男人女人午夜视频免费,免费人妻无码不卡中文字幕系,国产A级三级三级三级,成年无码aⅴ片在线观看

核因子κB受體激活因子(RANk)活性蛋白

Active Receptor Activator Of Nuclear Factor Kappa B (RANk)

CD265; TNFRSF11A; TNFRSF11-A; ODFR; OFE; TRANCER; Osteoclast differentiation factor receptor; Tumor Necrosis Factor Receptor Superfamily,Member 11a,NFKB Activator

  • 核因子κB受體激活因子(RANk)活性蛋白產(chǎn)品包裝(模擬)
  • 核因子κB受體激活因子(RANk)活性蛋白產(chǎn)品包裝(模擬)
  • 核因子κB受體激活因子(RANk)活性蛋白Figure. Gene Sequencing (Extract)
  • APC057Hu01.pngFigure. SDS-PAGE
  • 核因子κB受體激活因子(RANk)活性蛋白Figure. Western Blot
  • Certificate通過ISO 9001、ISO 13485質(zhì)量體系認證

活性實驗

Figure. The binding activity of TNFRSF11A with TRAF5.
RANK tumor necrosis factor receptor superfamily member 11A protein (TNFRSF11A) also known as receptor Activator of Nuclear Factor κ B (RANK) or TRANCE Receptoris a member of the tumor necrosis factor receptor (TNFR) molecular sub-family. TNFRSF11A is the receptor for RANK-Ligand (RANKL) and part of the RANK/RANKL/OPG signaling pathway that regulates osteoclast differentiation and activation. It is associated with bone remodeling and repair, immune cell function, lymph node development, thermal regulation, and mammary gland development. Besides, TNF Receptor Associated Factor 5 (TRAF5) has been identified as an interactor of TNFRSF11A, thus a binding ELISA assay was conducted to detect the interaction of recombinant human TNFRSF11A and recombinant human TRAF5. Briefly, TNFRSF11A were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to TRAF5-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TNFRSF11A pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF11A and TRAF5 was shown in Figure 1, and this effect was in a dose dependent manner.

用法

Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲存

避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。

相關(guān)產(chǎn)品

編號適用物種:Homo sapiens (Human,人)應用(僅供研究使用,不用于臨床診斷!)
RPC057Hu01核因子κB受體激活因子(RANk)重組蛋白Positive Control; Immunogen; SDS-PAGE; WB.
APC057Hu01核因子κB受體激活因子(RANk)活性蛋白Cell?culture;?Activity?Assays.
PAC057Hu01核因子κB受體激活因子(RANk)多克隆抗體WB,IHC
MAC057Hu22核因子κB受體激活因子(RANk)單克隆抗體WB; IHC; ICC; IP.
MAC057Hu21核因子κB受體激活因子(RANk)單克隆抗體WB
SEC057Hu核因子κB受體激活因子(RANk)檢測試劑盒(酶聯(lián)免疫吸附試驗法)Enzyme-linked immunosorbent assay for Antigen Detection.
LMC057Hu核因子κB受體激活因子(RANk)等多因子檢測試劑盒(流式熒光發(fā)光法)FLIA Kit for Antigen Detection.

參考文獻

雜志參考文獻
European Journal of ImmunologyHuman polymorphonuclear neutrophils express the receptor activator of NFκB (RANK) and are activated by its ligand RANKL[Wiley: source]
International Journal of Cardiology Valvular osteoclasts in calcification and aortic valve stenosis severity[PubMed: 23452891]
Bulletin? of? Experimental? Biology? and? MedicineReceptor Activator of Nuclear Transcription Factor NF-κB(RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors[DOI:110.1007/s10517-017-3832-9]
BIOSCIENCE REPORTSIL-38 restrains inflammatory response of collagen-induced arthritis in rats via SIRT1/HIF-1α signaling pathway[Pubmed: 32347300]